TY - JOUR
T1 - Circulating tumor DNA analysis in breast cancer
T2 - Is it ready for prime-time?
AU - Buono, Giuseppe
AU - Gerratana, Lorenzo
AU - Bulfoni, Michela
AU - Provinciali, Nicoletta
AU - Basile, Debora
AU - Giuliano, Mario
AU - Corvaja, Carla
AU - Arpino, Grazia
AU - Del Mastro, Lucia
AU - De Placido, Sabino
AU - De Laurentiis, Michele
AU - Cristofanilli, Massimo
AU - Puglisi, Fabio
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2019/2
Y1 - 2019/2
N2 - Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocation, treatment optimization with a potential side-effects reduction and consequent impact on quality of life and survival. This revolution is being catalyzed by liquid biopsy technologies, which provide prognostic and predictive information for advanced cancer patients, without the analytical and procedural drawbacks of tissue-biopsy. In particular, circulating tumor DNA (ctDNA) is gaining momentum as a clinically feasible option capable to capture both spatial and temporal tumor heterogeneity. Several techniques are currently available for ctDNA extraction and analysis, each with its preferential case scenarios and preanalytical implications which must be taken into consideration to effectively support clinical decision-making and to better highlight its clinical utility. Aim of this review is to summarize both analytical developments and clinical evidences to offer a comprehensive update on the deployment of ctDNA in breast cancer's (BC) characterization and treatment.
AB - Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocation, treatment optimization with a potential side-effects reduction and consequent impact on quality of life and survival. This revolution is being catalyzed by liquid biopsy technologies, which provide prognostic and predictive information for advanced cancer patients, without the analytical and procedural drawbacks of tissue-biopsy. In particular, circulating tumor DNA (ctDNA) is gaining momentum as a clinically feasible option capable to capture both spatial and temporal tumor heterogeneity. Several techniques are currently available for ctDNA extraction and analysis, each with its preferential case scenarios and preanalytical implications which must be taken into consideration to effectively support clinical decision-making and to better highlight its clinical utility. Aim of this review is to summarize both analytical developments and clinical evidences to offer a comprehensive update on the deployment of ctDNA in breast cancer's (BC) characterization and treatment.
KW - Circulating tumor DNA
KW - Liquid biopsy
KW - Longitudinal molecular assessment
KW - Next generation sequencing
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85060310811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060310811&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2019.01.004
DO - 10.1016/j.ctrv.2019.01.004
M3 - Review article
C2 - 30682661
AN - SCOPUS:85060310811
SN - 0305-7372
VL - 73
SP - 73
EP - 83
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
ER -
